Showcasing Development & Advantages of RB-601: A First-in-Class c-MET/EGFR Bispecific Nano ADC

  • Undergoing development of RB-601, a bispecific nano ADC
  • Highlighting RRB-601 advantages against classical bispecific ADCs across tumour tissue penetration, improved anti-tumour activity and superior tolerability profile
  • Exploring ongoing biomarker and clinical trial with potential across solid tumour indications